• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Sichenzia Ross Ference Carmel LLP Achieves Firm Record Advising on Over 170 Transactions Totaling Over $14 Billion in 2025

    1/20/26 8:00:00 AM ET
    $EMIS
    $NCRA
    $SOUL
    $STEX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Farming/Seeds/Milling
    Consumer Staples
    Get the next $EMIS alert in real time by email

    NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Sichenzia Ross Ference Carmel LLP ("SRFC") reported that in 2025 it advised on over 170 announced transactions, with the total value of these transactions exceeding $14 billion, far surpassing the firm's strong performance in 2024. The transactions, on behalf of various market participants, such as issuers, underwriters and investors, included initial public offerings, secondary public offerings, registered direct offerings, private placements, mergers, acquisitions and cryptocurrency transactions.

    In October of 2025, for the fifth consecutive quarter, SRFC was ranked first in the nation for issuer counsel among securities law firms in PlacementTracker's PIPE and Private Placement Markets League Tables for Q3 2025.

    Notable transaction highlights from 2025 include the following representations:

    • Soulpower Acquisition Corporation (NYSE:SOUL) in a definitive business combination agreement with SWB LLC, valued at approximately $8.1 billion.



    • Streamex Corp. (formerly BioSig Technologies, Inc.) (NASDAQ:STEX) in its $1.1 billion growth financing arrangements.



    • Sharps Technology, Inc. (NASDAQ:STSS, STSSW)) in a $400 million private placement.



    • Nocera, Inc. (NASDAQ:NCRA) in a private placement of up to $300 million.



    • Emmis Acquisition Corp. (NASDAQ:EMIS, EMISR)) in its $100 million SPAC initial public offering.



    "The incredible results of our firm's work this past year impresses but doesn't surprise me or any other attorney on this team. Each year, SRFC grows and expands its client base by providing exemplary services and doing right by our clients. It's only natural that more and more companies would take notice of our results and want to retain us as well," said Gregory Sichenzia, founding partner at SRFC. "Prominent entrepreneurs and business leaders want their legal needs handled by the industry's best, and when it comes to complex securities transactions, there's no one better than SRFC. I expect our team to build upon this incredible momentum in 2026."

    "Our firm has been building to this level of success for a while now, as our growing team of talented attorneys have advised on transactions of all kinds across a vast spectrum of industries," said Ross Carmel, named partner at SRFC. "We want to thank our clients, partners and colleagues for an incredible year in 2025 and cannot wait to see continued success throughout this year."

    A full list of the firm's transactions can be found here.

    About Sichenzia Ross Ference Carmel LLP

    SRFC is a nationally recognized law firm of approximately 70 attorneys with corporate, securities, litigation, trusts and estates and tax practices, serving clients from all over the world. Our mission is to solve our clients' most complicated legal problems and achieve their business goals in an expeditious, commercial and innovative manner.

    www.srfc.law

    Media Contact:

    [email protected]

    This press release may constitute attorney advertising. Prior results do not guarantee a similar outcome. The information in this press release is for general informational purposes only and should not be construed as legal advice or a substitute for obtaining legal advice from an attorney.



    Primary Logo

    Get the next $EMIS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EMIS
    $NCRA
    $SOUL
    $STEX

    CompanyDatePrice TargetRatingAnalyst
    Streamex Corp.
    $STEX
    11/25/2025$12.00Buy
    Needham
    More analyst ratings

    $EMIS
    $NCRA
    $SOUL
    $STEX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Needham initiated coverage on Streamex Exchange Corporation with a new price target

    Needham initiated coverage of Streamex Exchange Corporation with a rating of Buy and set a new price target of $12.00

    11/25/25 7:59:34 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $EMIS
    $NCRA
    $SOUL
    $STEX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Streamex Corp. to Present at the 38th Annual ROTH Conference

    WINTER PARK, Fla., March 19, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a technology and infrastructure company focused on the tokenization of commodity real-world assets, today announced Morgan Lekstrom, Co-Founder and Executive Chairman, and Russell Starr, Head of Capital Markets, will present at the 38th Annual ROTH Conference in Dana Point, California. The management team will present on a panel discussion titled The Future of Finance - Bridging DeFi and TradFi for Scaled Adoption. As institutional interest in digital assets reaches an inflection point, Streamex's management team will outline how the Company is positioning its technology to mo

    3/19/26 8:30:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. Appoints Christine Plummer, Former Global Controller at Coinbase and Managing Director at Morgan Stanley, as Chief Financial Officer

    WINTER PARK, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a technology and infrastructure company focused on the tokenization of commodity real-world assets, today announced the appointment of Christine Plummer, former Global Controller at Coinbase and Managing Director at Morgan Stanley, as Chief Financial Officer of Streamex. In this role, Ms. Plummer is expected to oversee the Company's global finance organization, including financial reporting, regulatory compliance, and financial operations as Streamex continues expanding its institutional platform and launching tokenized commodity products. Henry McPhie, Co-Founder & CEO of Str

    3/16/26 7:30:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. Appoints Shawn Matthews, Former CEO of Cantor Fitzgerald & Co. & Founder and CIO of Hondius Capital Management, to Board of Directors

    WINTER PARK, Fla., March 03, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a leader in institutional-grade tokenization and digital asset infrastructure, today is excited to announce the appointment of Shawn Matthews, Former CEO of Cantor Fitzgerald & Co. and Founder and Chief Investment Officer of Hondius Capital Management, to its Board of Directors. In this role, Mr. Matthews will bring decades of global investment, trading, and executive leadership experience to support Streamex's strategic growth, capital markets initiatives, and governance. He is joining as an independent director. Morgan Lekstrom, Co-Founder & Executive Chairman of Streamex sa

    3/3/26 7:30:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $EMIS
    $NCRA
    $SOUL
    $STEX
    SEC Filings

    View All

    Streamex Corp. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - Streamex Corp. (0001530766) (Filer)

    3/6/26 4:01:51 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Soulpower Acquisition Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Financial Statements and Exhibits

    8-K - Soulpower Acquisition Corp. (0002025608) (Filer)

    2/25/26 5:00:28 PM ET
    $SOUL
    Publishing
    Consumer Discretionary

    Sharps Technology Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Leadership Update

    8-K - Sharps Technology Inc. (0001737995) (Filer)

    2/23/26 4:15:27 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    $EMIS
    $NCRA
    $SOUL
    $STEX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Matthews Shawn claimed ownership of 100,000 shares (SEC Form 3)

    3 - Streamex Corp. (0001530766) (Issuer)

    3/9/26 4:01:18 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Marciano Anthony Mark was granted 100,000 shares (SEC Form 4)

    4 - Streamex Corp. (0001530766) (Issuer)

    2/24/26 6:07:38 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Executive Chairman Lekstrom Morgan Lee bought $50,000 worth of shares (20,000 units at $2.50) (SEC Form 4)

    4 - Streamex Corp. (0001530766) (Issuer)

    2/18/26 1:41:34 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $EMIS
    $NCRA
    $SOUL
    $STEX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Executive Chairman Lekstrom Morgan Lee bought $50,000 worth of shares (20,000 units at $2.50) (SEC Form 4)

    4 - Streamex Corp. (0001530766) (Issuer)

    2/18/26 1:41:34 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Large owner Giustra Frank bought $317,000 worth of shares (100,000 units at $3.17) (SEC Form 4)

    4 - Streamex Corp. (0001530766) (Issuer)

    2/4/26 7:04:10 PM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Director Lekstrom Morgan Lee bought $71,910 worth of shares (23,500 units at $3.06) (SEC Form 4)

    4 - Streamex Corp. (0001530766) (Issuer)

    2/3/26 11:32:53 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $EMIS
    $NCRA
    $SOUL
    $STEX
    Leadership Updates

    Live Leadership Updates

    View All

    Streamex Corp. Appoints Christine Plummer, Former Global Controller at Coinbase and Managing Director at Morgan Stanley, as Chief Financial Officer

    WINTER PARK, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a technology and infrastructure company focused on the tokenization of commodity real-world assets, today announced the appointment of Christine Plummer, former Global Controller at Coinbase and Managing Director at Morgan Stanley, as Chief Financial Officer of Streamex. In this role, Ms. Plummer is expected to oversee the Company's global finance organization, including financial reporting, regulatory compliance, and financial operations as Streamex continues expanding its institutional platform and launching tokenized commodity products. Henry McPhie, Co-Founder & CEO of Str

    3/16/26 7:30:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. Appoints Shawn Matthews, Former CEO of Cantor Fitzgerald & Co. & Founder and CIO of Hondius Capital Management, to Board of Directors

    WINTER PARK, Fla., March 03, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a leader in institutional-grade tokenization and digital asset infrastructure, today is excited to announce the appointment of Shawn Matthews, Former CEO of Cantor Fitzgerald & Co. and Founder and Chief Investment Officer of Hondius Capital Management, to its Board of Directors. In this role, Mr. Matthews will bring decades of global investment, trading, and executive leadership experience to support Streamex's strategic growth, capital markets initiatives, and governance. He is joining as an independent director. Morgan Lekstrom, Co-Founder & Executive Chairman of Streamex sa

    3/3/26 7:30:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. (NASDAQ: STEX) Appoints Morgan Lekstrom as Executive Chairman, and Announces Completed Repayment of Convertible Debenture and Cancellation of SEPA

    WINTER PARK, Fla., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a leader in institutional-grade tokenization and digital asset infrastructure, today announced that its Co-Founder and Chairman, Morgan Lekstrom, has been named Executive Chairman and will join the executive leadership team. The Company has also announced that the previously entered into Secured Convertible Debentures with YA II PN, LTD., a Cayman Islands exempt limited company ("Yorkville" or "Holder") have been fully repaid and the Standby Equity Purchase Agreement (the "SEPA") previously entered into with Yorkville has been cancelled. "I am honoured and excited to step int

    2/9/26 8:00:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $EMIS
    $NCRA
    $SOUL
    $STEX
    Financials

    Live finance-specific insights

    View All

    Streamex Corp. (NASDAQ: STEX) Acquires 9.9% Strategic Equity Stake in Royalty and Streaming Firm Empress Royalty Corp. Through a Premium Priced Share-for-Share Transaction at US$5.00 STEX with a Leading Institutional Investment Firm

    LOS ANGELES, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Streamex Corp. ("Streamex" or the "Company") (NASDAQ:STEX), a leader in institutional-grade tokenization and real-world asset infrastructure, today announced that it has acquired a 9.9% equity interest in Empress Royalty Corp. ("Empress") (TSXV:EMPR) through a strategic share purchase from Terra Capital Natural Resources Fund Pty Ltd. ("Terra Capital"), a prominent institutional investor. Under the executed Share Purchase Agreement, Streamex acquired 12,671,297 common shares of Empress in exchange for 2,443,750 restricted common shares of Streamex at a US$5.00 STEX share price, representing a premium to the current market price of STEX and an

    12/11/25 8:00:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Streamex Corp. (NASDAQ: STEX) Announces Launch of $100,000,000 USD GLDY Pre-Sale – A Gold-Backed Yield Generating Stablecoin Offering Institutional Yield on Physical Gold Bullion

    The launch of Streamex's $100 million USD GLDY pre-sale marks a historic opportunity for gold investors. Investing in gold is no longer just a static store of value, Streamex, through GLDY has created a yield-generating, institutional grade asset designed to offer both spot gold exposure and yield paid in additional ounces of physical gold bullion.  Key Highlights Gold Price Exposure and Gold-Denominated Distributions: GLDY is designed to combine audited physical bullion holdings with yield from institutionally managed gold leases sourced through Monetary Metals. GLDY seeks to provide exposure to the price of gold while targeting periodic distributions paid in additional ounces of gold.Rev

    11/10/25 8:30:00 AM ET
    $STEX
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Sharps Technology, Inc. Acquires Over 2 Million SOL, the Native Asset of Solana, the Fastest and Most Used Public Blockchain

    NEW YORK, Sept. 2, 2025 /PRNewswire/ -- Sharps Technology, Inc. (the "Company" or "Sharps Technology") (Nasdaq: "STSS" and "STSSW") today announced its first acquisition of Solana ("SOL") tokens as part of its digital asset treasury strategy under which the principal holding will be SOL, the native digital asset of the Solana blockchain. Funded from the Company's recent PIPE equity raise, Sharps Technology now holds over 2 million SOL, creating a SOL treasury currently valued north of $400M. Sharps Technology intends to provide regular updates on its SOL holdings and performan

    9/2/25 7:00:00 AM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    $EMIS
    $NCRA
    $SOUL
    $STEX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Sharps Technology Inc.

    SC 13G/A - Sharps Technology Inc. (0001737995) (Subject)

    11/13/24 4:50:17 PM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Sharps Technology Inc.

    SC 13G/A - Sharps Technology Inc. (0001737995) (Subject)

    10/9/24 9:01:14 AM ET
    $STSS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G filed by Sharps Technology Inc.

    SC 13G - Sharps Technology Inc. (0001737995) (Subject)

    2/14/24 11:14:11 AM ET
    $STSS
    Medical/Dental Instruments
    Health Care